Showing 2531-2540 of 7016 results for "".
Protecting the Vulnerable from COVID-19: A Street Physician’s Perspective
https://reachmd.com/programs/covid-19-frontlines/protecting-the-vulnerable-from-covid-19-a-street-physicians-perspective/11450/Most Americans are staying home to help control the COVID-19 pandemic, but what happens when a home is made up of cardboard boxes on the street?Research Efforts in the Race to Find a Cure for COVID-19
https://reachmd.com/programs/covid-19-frontlines/research-efforts-in-the-race-to-find-a-cure-for-covid-19/11579/This research team shifted from studying Castleman disease to COVID-19. Could the similarities between these two diseases help uncover a cure? Could similarities between Castleman disease and COVID-19 help us find a cure?A Look at Immunizations Through Time
https://reachmd.com/programs/covid-19-frontlines/a-look-at-immunizations-through-time/11580/Immunization techniques have been evolving since the 1100s. Could the techniques of the past help us in our current hunt for a COVID-19 vaccine?Conquer the Clutter: Strategies to Identify, Manage, & Overcome Hoarding
https://reachmd.com/programs/book-club/conquer-the-clutter-strategies-to-identify-manage-overcome-hoarding/11245/As many as 21 million Americans may be living with hoarding disorder. How can we help them reclaim their lives from the clutter that’s taken over?Guselkumab in Skin of Color: Results from a Randomized Phase 3b Psoriasis Trial
https://reachmd.com/programs/dermconsult/guselkumab-in-skin-of-color-results-from-a-randomized-phase-3b-psoriasis-trial/36371/Disparities in Acne Prescribing Patterns Highlight Structural and Racial Gaps
https://reachmd.com/programs/clinicians-roundtable/acne-prescribing-disparities-structural-racial-gaps/49091/Understanding the Mechanism Behind a Treatment Approach in Indolent Systemic Mastocytosis (ISM)
https://reachmd.com/programs/medical-industry-feature/mechanism-treatment-approach-indolent-systemic-mastocytosis-ism/32766/Historically, indolent systemic mastocytosis (ISM) care focused on treating symptoms. AYVAKIT® (avapritinib) targets the KIT D816V mutation, the underlying cause of ISM.3,4 Learn how AYVAKIT can play a role in treating patients with ISM.1New Frontiers in Severe Asthma Management
https://reachmd.com/programs/clinicians-roundtable/new-frontiers-in-severe-asthma-management/54213/Advances in biologic therapies are transforming severe asthma management, enabling improved symptom control, reduced steroid use, and the potential to step down inhaled treatments. Hear Dr. Geoffrey Chupp share his thoughts on emerging therapies and how they may reshape care and move patients closerAddressing Unmet Needs in Metastatic Uveal Melanoma
https://reachmd.com/programs/cme/addressing-unmet-needs-in-metastatic-uveal-melanoma/48980/Dive into what sets metastatic uveal melanoma (mUM) apart from cutaneous melanoma and why that matters for clinical decision-making. Explore how HLA A*02:01 typing informs patient selection and how bispecific TCR therapy is changing the treatment landscape. Real-world cases and clinical trial data bApplying the 2024 McDonald Criteria: Real-World Impacts on MS Diagnosis
https://reachmd.com/programs/neurofrontiers/mcdonald-criteria-impacts-ms-diagnosis/56634/Early real-world experience with the 2024 McDonald criteria suggests a meaningful increase in multiple sclerosis (MS) diagnoses, driven largely by recognition of optic nerve involvement and reclassification of radiologically isolated syndrome. Hear from Dr. Aaron Miller as he reviews emerging